|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
European Association for the Study of the
Liver. Electronic address, . simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver: EASL clinical
practice guidelines: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu RX, Seto WK, Lai CL and Yuen MF:
Epidemiology of hepatocellular carcinoma in the asia-pacific
region. Gut Liver. 10:332–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buonaguro L, Mauriello A, Cavalluzzo B,
Petrizzo A and Tagliamonte M: Immunotherapy in hepatocellular
carcinoma. Ann Hepatol. 18:291–297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Rd THW, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Leonardi GC, Candido S, Cervello M,
Nicolosi D, Raiti F, Travali S, Spandidos DA and Libra M: The tumor
microenvironment in hepatocellular carcinoma (review). Int J Oncol.
40:1733–1747. 2012.PubMed/NCBI
|
|
10
|
Shalapour S, Lin XJ, Bastian IN, Brain J,
Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, et
al: Inflammation-induced IgA+ cells dismantle anti-liver
cancer immunity. Nature. 551:340–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye L, Zhang Q, Cheng Y, Chen X, Wang G,
Shi M, Zhang T, Cao Y, Pan H, Zhang L, et al: Tumor-derived
exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by
promoting TIM-1(+) regulatory B cell expansion. J Immunother
Cancer. 6:1452018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xue H, Lin F, Tan H, Zhu ZQ, Zhang ZY and
Zhao L: Overrepresentation of IL-10-expressing B cells suppresses
cytotoxic CD4+ T cell activity in HBV-induced
hepatocellular carcinoma. PLoS One. 11:e01548152016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwartz M, Zhang Y and Rosenblatt JD: B
cell regulation of the anti-tumor response and role in
carcinogenesis. J Immunother Cancer. 4:402016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shaso Y, Lo CM, Ling CC, Liu XB, Ng KTP,
Chu AC, Ma YY, Li CX, Fan ST and Man K: Regulatory B cells
accelerate hepatocellular carcinoma progression via CD40/CD154
signaling pathway. Cancer Lett. 355:264–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Ma L, Goswami S, Ma J, Zheng B,
Duan M, Liu L, Zhang L, Shi J, Dong L, et al: Landscape of
infiltrating B cells and their clinical significance in human
hepatocellular carcinoma. Oncoimmunology. 8:e15713882019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garnelo M, Tan A, Her Z, Yeong J, Lim CJ,
Chen J, Lim KH, Weber A, Chow P, Chung A, et al: Interaction
between tumour-infiltrating B cells and T cells controls the
progression of hepatocellular carcinoma. Gut. 66:342–351. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cabrita R, Lauss M, Sanna A, Donia M,
Larsen MS, Mitra S, Johansson I, Phung B, Harbst K,
Vallon-Christersson J, et al: Tertiary lymphoid structures improve
immunotherapy and survival in melanoma. Nature. 577:561–565. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Helmink BA, Reddy SM, Gao J, Zhang S,
Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et
al: B cells and tertiary lymphoid structures promote immunotherapy
response. Nature. 577:549–555. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petitprez F, de Reynies A, Keung EZ, Chen
TWW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A,
et al: B cells are associated with survival and immunotherapy
response in sarcoma. Nature. 577:556–560. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie S, Huang J, Qiao Q, Zang W, Hong S,
Tan H, Dong C, Yang Z and Ni L: Expression of the inhibitory B7
family molecule VISTA in human colorectal carcinoma tumors. Cancer
Immunol Immunother. 67:1685–1694. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stuart T, Butler A, Hoffman P, Hafemeister
C, Papalexi E, Mauck WM III, Hao Y, Stoeckius M, Smibert P and
Satija R: Comprehensive integration of single-cell data. Cell.
177:1888–1902.e21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McInne L and Healy J: UMAP: Uniform
Manifold Approximation and Projection for Dimension Reduction.
ArXiv e-prints 1802.03426. 2018.https://arxiv.org/abs/1802.03426
|
|
23
|
Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao
R, Modak M, Carotta S, Haslinger C, Kind D, et al: Landscape and
dynamics of single immune cells in hepatocellular carcinoma. Cell.
179:829–845, e820. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li QX, Ke N, Sundaram R and Wong-Staal F:
NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in
cell apoptosis and carcinogenesis. Histol Histopathol. 21:533–540.
2006.PubMed/NCBI
|
|
25
|
Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M,
Hao J, Alekseev A, Khong H, Chen T, et al: Genome-wide analysis
identifies NR4A1 as a key mediator of T cell dysfunction. Nature.
567:525–529. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Lopez-Moyado IF, Seo H, Lio CWJ,
Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP and Rao A:
NR4A transcription factors limit CAR T cell function in solid
tumours. Nature. 567:530–534. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren Z, Peng H and Fu YX: PD-1 shapes B
cells as evildoers in the tumor microenvironment. Cancer Discov.
6:477–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Visser KE, Korets LV and Coussens LM:
De novo carcinogenesis promoted by chronic inflammation is B
lymphocyte dependent. Cancer Cell. 7:411–423. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andreu P, Johansson M, Affara NI, Pucci F,
Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al:
FcRγ activation regulates inflammation-associated squamous
carcinogenesis. Cancer Cell. 17:121–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin Z, Richter G, Schüler T, Ibe S, Cao X
and Blankenstein T: B cells inhibit induction of T cell-dependent
tumor immunity. Nat Med. 4:627–630. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hetta HF: Regulatory B cells: Key players
in hepatocellular carcinoma progression. Gastroenterology &
Hepatology. Open Access 52016. https://medcraveonline.com/GHOA/GHOA-05-00136.pdf
|
|
33
|
DiLillo DJ, Matsushita T and Tedder TF:
B10 cells and regulatory B cells balance immune responses during
inflammation, autoimmunity, and cancer. Ann NY Acad Sci.
1183:38–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shevach EM: From vanilla to 28 flavors:
Multiple varieties of T regulatory cells. Immunity. 25:195–201.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
von Boehmer H: Mechanisms of suppression
by suppressor T cells. Nat Immunol. 6:338–344. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin CY, Graca L, Cobbold SP and Waldmann
H: Dominant transplantation tolerance impairs CD8+ T
cell function but not expansion. Nat Immunol. 3:1208–1213. 2002.
View Article : Google Scholar : PubMed/NCBI
|
